menu

Category: Health

Category: Health

MTHFR Gene Testing: What Nucleus Reports

MTHFR Gene Testing: What Nucleus Reports

What Nucleus reports about MTHFR, why common variants are different from severe MTHFR deficiency, and how to find them in your DNA data.

Nucleus Science Team

Nucleus Science Team

What does the MTHFR gene do?

MTHFR (methylenetetrahydrofolate reductase) makes an enzyme that converts folate into its active form, 5-methyltetrahydrofolate. Your body uses that active folate to recycle homocysteine back into the amino acid methionine. When the enzyme doesn’t work, homocysteine builds up in the blood.

Does Nucleus test the MTHFR gene?

Yes. Nucleus analyzes MTHFR for severe MTHFR deficiency, which can also be referred to as homocystinuria due to MTHFR deficiency. A gene test like this one reads your DNA to look for variants in the MTHFR gene itself. That’s different from a homocysteine blood test, which measures the amount of homocysteine in your blood instead of looking at your DNA. It’s a recessive disorder, which means it happens only when a person inherits two disease-causing MTHFR variants, one from each parent. The enzyme then barely works, and homocysteine rises to very high levels.

These variants are rare. Severe MTHFR deficiency is one of the rarest inherited metabolic disorders. A 2017 international clinical guideline collected just 148 published cases worldwide (Huemer et al., 2017).

Severe MTHFR deficiency mainly affects the brain and nervous system. It usually appears in early childhood, though it can start at any age (Huemer et al., 2017):

  • Newborns and infants: feeding difficulties, reduced alertness, low muscle tone and pauses in breathing.

  • Older children: seizures and cognitive impairment.

  • Teenagers and adults: walking difficulties, nerve damage, or psychiatric and behavioral symptoms.

  • Blood clots: uncommon, and mostly seen in teenagers and adults.

Early diagnosis changes outcomes. The guideline strongly recommends betaine treatment, which “improves the outcome and prevents disease when given early.”

Most people with one of these variants are carriers. Carriers are healthy, but if both partners carry a variant, each child has a 1 in 4 chance of having the condition. Nucleus reports these rare, disease-causing MTHFR variants as part of our whole-genome analysis. If you’re planning a pregnancy or already expecting, this is the kind of result to bring up with your doctor or a genetic counselor when you talk about prenatal testing.

What about C677T and A1298C?

When people ask about MTHFR testing, they usually mean two common variants:

  • C677T (rs1801133, also referred to as c.665C>T)

  • A1298C (rs1801131, also referred to as c.1286A>C)

Many genetics apps and online reports link these to blood clots, miscarriage, heart disease, depression, anxiety and “poor methylation,” often with advice to take methylfolate. Having one of these common variants does not diagnose those conditions or show that you need methylfolate. We do not directly report either variant. Both variants are still in your data, and if you’re curious, we show you how to look them up yourself further down in this article.

Why doesn’t Nucleus report these common variants?

They’re extremely common. Both variants are carried by a large share of healthy people. About 11% of people of European ancestry and 21% of Latino ancestry carry two copies of C677T. About 10% of people of European ancestry and 17% of South Asian ancestry carry two copies of A1298C (gnomAD v4). These common genotypes do not, on their own, diagnose severe MTHFR deficiency or explain someone’s symptoms.

A biochemical effect is not the same as a useful disease prediction. A 1995 study linked C677T to reduced enzyme activity and raised homocysteine (Frosst et al., 1995). That biochemical effect does not establish that the variant causes blood clots, recurrent pregnancy loss or the many other conditions attributed to it online. ACMG finds little clinical value in routine testing for these common variants when assessing thrombophilia.

Clinical recommendations advise against routine testing. ACMG recommends against testing these common MTHFR variants when assessing thrombophilia or recurrent pregnancy loss. Its original 2013 guideline was reclassified as a clinical practice resource in a 2020 addendum.

What does FinnGen show? The FinnGen Biobank links DNA to health records for about 500,000 people in Finland. The release 13 analysis shown below compares C677T and A1298C with 2,754 diseases and traits. None of C677T’s associations in this analysis reaches the conventional genome-wide significance threshold (p < 5 × 10⁻⁸). Its strongest association, with folate deficiency anaemia, is p = 1.1 × 10⁻⁶. Falling short of this threshold does not prove there is no effect; it means the evidence does not meet that statistical standard.

C677T associations across FinnGen disease and trait categories. Folate deficiency anaemia is the strongest signal shown.

C677T’s associations with diseases in FinnGen. The strongest association shown is with folate deficiency anaemia (p = 1.1 × 10⁻⁶), below the conventional genome-wide significance threshold. The estimated odds ratio is about 1.5 per copy (β = 0.40). An odds ratio is not an absolute lifetime risk, and this association alone does not establish that routine C677T testing would improve care. View full-size chart.

A1298C’s blood pressure association needs context. A1298C is associated with hypertension in FinnGen (p = 5.3 × 10⁻¹⁶), but an association does not establish that A1298C itself causes the difference. Nearby variants are often inherited together. The regional analysis shows stronger associations nearby, including rs12567136 in CLCN6 (p = 4.0 × 10⁻⁴¹). Identifying a causal variant requires additional evidence, such as fine-mapping.

Associations from this region are also already counted in our hypertension polygenic risk score, alongside millions of other variants.

A1298C associations across FinnGen disease and trait categories, including hypertension and blood-pressure-related outcomes.

A1298C’s associations with diseases in FinnGen. The plot shows an association with hypertension; it does not establish that A1298C is the causal variant. View full-size chart.

A blood test answers the question better. If you’re worried about homocysteine or folate, ask your doctor to measure them directly. Your C677T genotype adds little to that result.

How can I find these variants in my data?

We don’t report these variants, but they’re in your data, and it’s your DNA. Here’s how to look them up yourself.

  1. Download your data. In the Nucleus app, go to Account settings or choose “Downloads” from the dropdown menu. You can download your whole genome as a file, including versions formatted for Promethease or GEDmatch upload. Either of those will be easiest to use.

  2. Open it and search. Open the file in a text editor and search for the rsIDs of interest.

  3. Read your genotype. Raw data files report the DNA strand opposite to the “C677T” and “A1298C” names, so the letters look different:

Variant

Genotype in your file

Copies of the variant

C677T (rs1801133)

GG

No copies

C677T (rs1801133)

AG

One copy

C677T (rs1801133)

AA

Two copies

A1298C (rs1801131)

TT

No copies

A1298C (rs1801131)

GT

One copy

A1298C (rs1801131)

GG

Two copies

Whatever you find, these common genotypes do not diagnose severe MTHFR deficiency and usually do not change clinical care on their own.

Common questions about MTHFR

Should I worry if I have two copies of C677T?

For most people, no. Two copies of C677T are common and do not mean you have severe MTHFR deficiency. If you have symptoms or concerns about folate or homocysteine, discuss them with your doctor, who can decide whether blood testing would help.

Do I need methylfolate instead of folic acid?

The US Preventive Services Task Force recommends a daily supplement containing 0.4–0.8 mg (400–800 micrograms) of folic acid for people planning to or who could become pregnant. CDC states that common MTHFR variants are not a reason to avoid folic acid or switch to methylfolate. People with a previous pregnancy affected by a neural tube defect or other high-risk circumstances need individual advice from their prenatal clinician.

Why do other genetic tests report these variants?

These variants became well known through early research, and many people still look for them. A measurable genetic association is not always useful for a clinical decision. Nucleus focuses its reports on findings with evidence supporting their interpretation.

What about my risk for common diseases?

These are shaped by many genetic variants with modest impacts individually, not one. Nucleus polygenic risk scores combine many variants to estimate genetic predisposition to common diseases. The value of a prediction depends on the condition and how the model was validated.

Where can I see what Nucleus reports?

Search “MTHFR”, or any other gene or condition, on the Nucleus gene list. It covers more than 2,000 conditions.

Sources

  • Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis 2017;40(1):21-48. doi:10.1007/s10545-016-9991-4

  • Hickey SE, Curry CJ, Toriello HV. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med 2013;15(2):153-156. doi:10.1038/gim.2012.165

  • Frosst P, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10(1):111-113. doi:10.1038/ng0595-111

  • US Preventive Services Task Force. Folic acid supplementation to prevent neural tube defects: recommendation statement. JAMA 2023;330(5):454-459.

  • gnomAD v4.1, genome data: rs1801133, rs1801131. Accessed 29 Oct 2026.

  • FinnGen release 13: rs1801133, rs1801131, hypertension region. Accessed 29 Oct 2026.

  • Nucleus gene list, https://app.mynucleus.com/explore

  • Nucleus FAQ (downloading your data), https://mynucleus.com/faq

  • CDC: MTHFR Gene Variant and Folic Acid Facts

  • ACMG 2020 addendum

  • USPSTF folic acid recommendation

Your best baby starts with two cheek swabs.

Your best baby starts with two cheek swabs.

Join our newsletter

Switch to Spanish

Join the movement

Switch to Spanish

Join the movement

Switch to Spanish